Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 10/20 | 0.51 |
| ▸ | GSK3B | P49841 | 8/20 | 0.51 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.51 |
| ▸ | PAK4 | O96013 | 4/20 | 0.51 |
| ▸ | GSK3A | P49840 | 3/20 | 0.51 |
| ▸ | IGF1R | P08069 | 2/20 | 0.51 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.51 |
| ▸ | JAK2 | O60674 | 1/20 | 0.51 |
| ▸ | ABL1 | P00519 | 1/20 | 0.51 |
| ▸ | LCK | P06239 | 1/20 | 0.51 |
| ▸ | FYN | P06241 | 1/20 | 0.51 |
| ▸ | CSF1R | P07333 | 1/20 | 0.51 |
| ▸ | RET | P07949 | 1/20 | 0.51 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.51 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.51 |
| ▸ | FLT1 | P17948 | 1/20 | 0.51 |
| ▸ | LTK | P29376 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | FLT3 | P36888 | 1/20 | 0.51 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10122870 | 0.82 | AURKA (0.52) | AURKAGSK3BAURKBPAK4GSK3A | |
| SCHEMBL3939475 | 0.79 | PAK4 (0.56) | AURKAGSK3BAURKBPAK4GSK3A | |
| SCHEMBL10312059 | 0.79 | AURKA (0.50) | AURKAGSK3BAURKBPAK4GSK3A | |
| SCHEMBL10277252 | 0.71 | APP (0.52) | — | |
| SCHEMBL10122871 | 0.70 | AURKA (0.64) | AURKAGSK3BAURKBPAK4GSK3A | |
| SCHEMBL10294569 | 0.70 | PAK4 (0.49) | AURKAGSK3BAURKBPAK4GSK3A | |
| SCHEMBL801702 | 0.70 | GSK3B (0.65) | AURKAGSK3BAURKBPAK4GSK3A | |
| SCHEMBL785406 | 0.69 | AURKA (0.70) | AURKAGSK3BAURKBPAK4GSK3A | |
| SCHEMBL30147253 | 0.69 | AURKA (0.70) | AURKAGSK3BAURKBPAK4GSK3A | |
| SCHEMBL596714 | 0.68 | GRM5 (0.39) | AURKAGSK3BAURKBPAK4GSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178758-A1 | STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120178758-A1 | STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178758-A1 | STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | STK25, STK35, SGK2 | AURKA 793/4885GSK3B 297/4885AURKB 584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.